Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II clinical trial, multicenter, open, uncontrolled, to evaluate the effectiveness of the combination of sorafenib and bevacizumab in the treatment of patients with advanced and/or metastatic neuroendocrine tumors [ENSAYO CLINICO DE FASE II, MULTICENTRICO, ABIERTO, NO CONTROLADO PARA EVALUAR LA EFICACIA DE LA COMBINACION DE SORAFENIB Y BEVACIZUMAB EN EL TRATAMIENTO DE PACIENTES CON TUMOR NEUROENDOCRINO AVANZADO Y/O METASTASICO]

Next Previous
Trial Profile

Phase II clinical trial, multicenter, open, uncontrolled, to evaluate the effectiveness of the combination of sorafenib and bevacizumab in the treatment of patients with advanced and/or metastatic neuroendocrine tumors [ENSAYO CLINICO DE FASE II, MULTICENTRICO, ABIERTO, NO CONTROLADO PARA EVALUAR LA EFICACIA DE LA COMBINACION DE SORAFENIB Y BEVACIZUMAB EN EL TRATAMIENTO DE PACIENTES CON TUMOR NEUROENDOCRINO AVANZADO Y/O METASTASICO]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Sorafenib (Primary)
  • Indications Neuroendocrine tumours
  • Focus Therapeutic Use
  • Acronyms GETNE0801

    • Most Recent Events

    • 23 Apr 2023 Results pooled analysis from SU11248, SUN1111), Pazopanib (PAZONET), sorafenib-bevacizumab (GETNE0801) and Lenvatinib (TALENT) published in the European Journal of Cancer
    • 24 Aug 2011 New trial record
    • 01 Sep 2009 Status changed from recruiting to completed according to results published in the European Journal of Cancer.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top